Niwa T, Yazawa T, Ise M, Sugano M, Kodama T, Uehara Y, Maeda K
Department of Internal Medicine, Nagoya University Branch Hospital, Japan.
Nephron. 1991;57(1):84-8. doi: 10.1159/000186222.
Serum indoxyl sulfate, which is markedly accumulated in uremic patients, cannot be removed efficiently by hemodialysis due to its albumin binding. To determine if oral adsorbent (AST-120) can decrease its serum concentration in uremic state, oral adsorbent was administered to experimental nephrectomized uremic rats. Uremic rats fed with oral adsorbent showed a significantly lower serum concentration of indoxyl sulfate compared to control uremic rats, even when serum concentrations of urea nitrogen and creatinine were not significantly decreased in the uremic rats fed with oral adsorbent. Indoxyl sulfate was detected only at a lower concentration in bile as compared with the serum of uremic rats. These results suggest that oral adsorbent adsorbs indole, a precursor of indoxyl sulfate, in the intestine and prevents the accumulation of indoxyl sulfate in uremic rats.
硫酸吲哚酚在尿毒症患者体内显著蓄积,由于其与白蛋白结合,血液透析无法有效清除。为了确定口服吸附剂(AST-120)能否降低尿毒症状态下的血清浓度,对实验性肾切除的尿毒症大鼠给予口服吸附剂。与对照尿毒症大鼠相比,喂食口服吸附剂的尿毒症大鼠血清硫酸吲哚酚浓度显著降低,即便喂食口服吸附剂的尿毒症大鼠尿素氮和肌酐的血清浓度并未显著降低。与尿毒症大鼠血清相比,仅在胆汁中检测到较低浓度的硫酸吲哚酚。这些结果表明,口服吸附剂在肠道中吸附硫酸吲哚酚的前体吲哚,从而防止尿毒症大鼠体内硫酸吲哚酚的蓄积。